Companies like Enveric Biosciences are taking a different approach by attempting to strip psychedelics of their hallucinogenic effects altogether. Enveric’s CEO Joseph Tucker suggests that a non-hallucinogenic version of psychedelics,…
Read More
In an era where mental health disorders such as depression and anxiety are among the leading causes of disability worldwide, the search for innovative treatments is more pressing than ever….
Enveric Biosciences ENVB recently announced that research highlighting the Company’s lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N,…
Psychedelics biotech company Enveric Biosciences has presented research highlighting its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit showing beneficial outcomes in preclinical models of anxiety and depression. EB-003…
Joseph Tucker, Ph.D., CEO of Enveric Biosciences, offered valuable insight into the issues spotlighted by the FDA’s decision. “The thematic challenges that came to light in the Lykos Adcomm largely…
Joseph Tucker, CEO and director at Enveric Biosciences, a biotech firm, suggested a pair of obstacles this study simply couldn’t overcome. “The thematic challenges that came to light in the…
Dr. Joseph Tucker, CEO of Enveric Biosciences, provided a broader perspective on the challenges highlighted by the FDA’s decision. “The thematic challenges that came to light in the Lykos Adcomm…
Enveric Biosciences, a forward-thinking biotechnology company specializing in neuroplastogenic treatments for neuropsychiatric disorders, has announced preclinical results that underscore the potential of their novel drug candidate, EB-003. These findings, detailed…
Psychedelics biotech Enveric Biosciences announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental…
